Erik Swain
Executive Editor at Endocrine Today
Medical journalist (cardiology), rock and roll fanatic, movie and TV buff.
Articles
-
1 week ago |
healio.com | Erik Swain
Key takeaways: Palopegteriparatide improved skeletal dynamics and renal function in patients with chronic hypoparathyroidism at 2 years. The drug was well tolerated and no new safety signals were detected. ORLANDO — Among patients with chronic hypoparathyroidism, palopegteriparatide improved skeletal dynamics and renal function at 2 years, according to new data from the PaTHway trial.
-
1 week ago |
healio.com | Erik Swain
• A transcatheter mitral valve replacement system was approved for patients at high surgical risk. • The system is fully repositionable and available in multiple sizes. Abbott announced the FDA approved its transcatheter mitral valve replacement system for patients with severe mitral annular calcification at high surgical risk for open-heart surgery or ineligible for mitral valve repair.
-
2 weeks ago |
healio.com | Erik Swain
Key takeaways: Veligrotug improved proptosis, diplopia and clinical activity score in patients with active or chronic thyroid eye disease at 15 weeks. An FDA approval decision is expected in the second half of 2026. ORLANDO — In patients with active or chronic thyroid eye disease, veligrotug improved symptoms of proptosis and diplopia and clinical activity score, according to 15-week results of the THRIVE and THRIVE-2 trials.
-
2 weeks ago |
healio.com | Scott Buzby |Erik Swain |Katie Kalvaitis
First transcatheter valve approved for use in asymptomatic patients. Recent FDA updates in the areas of cardiac intervention, hypertension and arrhythmia disorders expand the pool of available treatments to new patient populations. This FDA Recap highlights FDA approval of the first transcatheter aortic valve replacement system for treatment of asymptomatic aortic stenosis and the first leadless left ventricular endocardial pacing device.
-
2 weeks ago |
healio.com | Erik Swain
Key takeaways: Patients with obesity who took semaglutide had lower risk for fractures vs. those who had sleeve gastrectomy. More research is needed to determine the relationship between semaglutide and bone health. ORLANDO — In a retrospective cohort study using propensity matching, among patients with obesity, those taking semaglutide had lower risk for fractures than those who underwent sleeve gastrectomy.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 41
- Tweets
- 14
- DMs Open
- No
RT @Katie_Kalvaitis: The @CardiologyToday and @GoHealio team wears red in support of national #WearRedDay to raise awareness of #heartdisea…
We had a thrilling time in Munich covering #ESCCongress. Here are our interviews with prominent interventional cardiologists about their highlights from the meeting. https://t.co/h8UyA3ea8v @DLBHATTMD @drmortkern @Drroxmehran @AshishPershad
"In this November/December issue of Cardiology Today’s Intervention, we cover one of the fastest-moving areas in endovascular intervention: catheter-based therapy for pulmonary embolism and deep vein thrombosis." -- @DLBHATTMD https://t.co/IqMahV0CCC
